Back to the future: Multiagent chemotherapy in ovarian cancer revisited

被引：8

作者：

Cannistra, SA ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1999年 / 17卷 / 03期

关键词：

D O I：

10.1200/JCO.1999.17.3.741

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：741 / 743

页数：3

相关论文

共 13 条

[1]

[Anonymous], 1985, NEW ENGL J MED, V312, P1465

[2] MEDICAL PROGRESS - CANCER OF THE OVARY [J].

CANNISTRA, SA .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21) :1550-1559

[3] Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study [J].

Creemers, GJ ;

Bolis, G ;

Gore, M ;

Scarfone, G ;

Lacave, AJ ;

Guastalla, JP ;

Despax, R ;

Favalli, G ;

Kreinberg, R ;

VanBelle, S ;

Hudson, I ;

Verweij, J ;

Huinink, WWT .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) :3056-3061

[4]

GOLDIE JH, 1982, CANCER TREAT REP, V66, P439

[5] Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer [J].

Herben, VMM ;

Panday, VRN ;

Richel, DJ ;

Schellens, JHM ;

van der Vange, N ;

Rosing, H ;

Beusenberg, FD ;

Hearn, S ;

Doyle, E ;

Beijnen, JH ;

Huinink, WWT .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :747-755

[6] CANCER OF THE ANAL-CANAL - MODEL FOR PREOPERATIVE ADJUVANT COMBINED MODALITY THERAPY [J].

LEICHMAN, L ;

NIGRO, N ;

VAITKEVICIUS, VK ;

CONSIDINE, B ;

BUROKER, T ;

BRADLEY, G ;

SEYDEL, HG ;

OLCHOWSKI, S ;

CUMMINGS, G ;

LEICHMAN, C ;

BAKER, L .

AMERICAN JOURNAL OF MEDICINE, 1985, 78 (02) :211-215

[7] Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].

McGuire, WP ;

Hoskins, WJ ;

Brady, MF ;

Kucera, PR ;

Partridge, EE ;

Look, KY ;

ClarkePearson, DL ;

Davidson, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6

[8] Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation [J].

Muggia, FM ;

Hainsworth, JD ;

Jeffers, S ;

Miller, P ;

Groshen, S ;

Tan, M ;

Roman, L ;

Uziely, B ;

Muderspach, L ;

Garcia, A ;

Burnett, A ;

Greco, FA ;

Morrow, CP ;

Paradiso, LJ ;

Liang, LJ .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :987-993

[9] RANDOMIZED TRIAL COMPARING 2 COMBINATION CHEMOTHERAPY REGIMENS (CHAP-5 V CP) IN ADVANCED OVARIAN-CARCINOMA [J].

NEIJT, JP ;

TENBOKKELHUININK, WW ;

VANDERBURG, MEL ;

VANOOSTEROM, AT ;

WILLEMSE, PHB ;

HEINTZ, APM ;

VANLENT, M ;

TRIMBOS, JB ;

BOUMA, J ;

VERMORKEN, JB ;

VANHOUWELINGEN, JC .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (08) :1157-1168

[10] Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A gynecologic oncology group study [J].

OReilly, S ;

Fleming, GF ;

Baker, SD ;

Walczak, JR ;

Bookman, MA ;

McGuire, WP ;

Schilder, RJ ;

Alvarez, RD ;

Armstrong, DK ;

Horowitz, IR ;

Ozols, RF ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :177-186